Status:
COMPLETED
Elaboration of a Prioritization Score for Pharmaceutical Interviews in Patients Treated With Oral Anticoagulants
Lead Sponsor:
CHU de Reims
Conditions:
Thromboembolic Event
Eligibility:
All Genders
18+ years
Brief Summary
Oral anticoagulants have a prominent place in the strategy of prevention and treatment of thromboembolic diseases, especially in patients with atrial fibrillation. However, a study conducted by the Na...
Detailed Description
Oral anticoagulants are represented by two classes: vitamin K antagonists (VKA) and non-VKA oral anticoagulants (DOAC). They have a prominent place in the strategy of prevention and treatment of throm...
Eligibility Criteria
Inclusion
- For the case-subjects:
- Patient hospitalized at the Reims university hospital
- Patient treated with an oral anticoagulant (vitamin K antagonist: VKA or non-VKA oral anticoagulant: DOAC) since at least one month
- Patient with a serious hemorrhage or a thromboembolic event.
- For the control-subjects:
- Patient hospitalized at the Reims university hospital
- Patient treated with an oral anticoagulant (vitamin K antagonist: VKA or non-VKA oral anticoagulant: DOAC) since at least one month
- Without a serious hemorrhage or a thromboembolic event.
Exclusion
- Patient physically or mentally not able to express non-opposition or opposition to the study;
- Patient protected by law;
- Patient physically or mentally not able to answer the surveys;
- Patient hospitalized in the month preceding the inclusion;
- Patient discharged from hospital before having answering the surveys.
Key Trial Info
Start Date :
September 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT06100380
Start Date
September 20 2020
End Date
October 1 2023
Last Update
May 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Reims
Reims, France, 51092